CSX said it expects revenue to fall as much as 2% in 2019, well below a previous forecast of an increase of 1% to 2%.Marketsread more
Challenging conditions in the U.S. housing market, along with tighter currency controls by the Chinese government, cause a stunning drop in foreign demand for American homes.Real Estateread more
The growth in net interest income, a main engine of the industry's profit, looks to slow to a halt in the back half of this year.Banksread more
Amazon also said that on Monday and Tuesday it sold more Amazon devices — like the Echo Dot, the Fire TV Stick and Alexa Voice Remote — over a two-day period than it ever has...Retailread more
The news comes after eBay announced a strategic portfolio review on March 1.The Faber Reportread more
If the S&P 500 climbs another 4%, it will have doubled the peak reached in the previous bull market, Michael Santoli notes.Trading Nationread more
Ascending triangle patterns have been appearing across the stock market, and they tend to be precursors to higher prices, says Miller Tabak's Matt Maley.Trading Nationread more
Netflix reports earnings Wednesday as it loses licensed shows to rivals launching their own streaming services.Technologyread more
Hedge fund manager Kyle Bass reportedly thinks that U.S. interest rates will plummet toward zero in 2020 as the economy heads for recession.Hedge Fundsread more
Shares of beauty and wellness products company Nu Skin tanked on Wednesday after the company said China's crackdown on health products is weighing on sales.Investingread more
Buying stocks when they are this expensive has historically led to lower returns, data compiled by Ned Davis Research shows.Marketsread more
Check out which companies are making headlines before the bell:
Walgreen–The drug store operator earned 91 cents per share for its third quarter, missing estimates by three cents, with revenue also falling below consensus. The company cites pressure on pharmacy profit margins, although it notes Walgreen is seeing overall top line growth.
Micros Systems–The hardware and software producer would pay Oracle a breakup fee of about $157.78 million, if the deal to buy Micros for $5.3 billion is not completed. That information comes from a Securities and Exchange Commission filing.
Vertex Pharmaceuticals–A Vertex treatment for cystic fibrosis performed well in late stage clinical trials, and the drug company plans to submit it for FDA approval during the fourth quarter.
Navistar–The heavy equipment maker has amended its stockholder rights plan, saying it has converted it into a tax asset protection plan. The plan would limit tax benefits in the event of an ownership change.
Dr Pepper Snapple–The beverage maker's shares were downgraded to "neutral" from "buy" at Citi, noting that the stock's 22 percent year-to-date increase has far outpaced its rivals, and that it may be time for a breather.
Micron Technology —The chip maker reported fiscal third quarter profit of 79 cents per share, excluding certain items, nine cents above estimates. Revenue also came in slightly above consensus, with the company saying rebounding personal computer demand helped boost sales of its DRAM chips.
Dean Foods–The company has been subpoenaed in connection with an insider trading probe of investor Carl Icahn, according to the Wall Street Journal. The paper said the SEC also contacted Clorox in 2011 for information related to trading in the company's shares.
Allergan–The company plans to raise its earnings outlook when it reports its latest quarterly earnings results, according to CEO David Pyott. The comments came as Pyott and Allergan's board urged investors not to sell their shares to Valeant Pharmaceuticals, which has gone directly to shareholders in its bid to acquire Allergan.
Avon Products–The cosmetics maker will cut about 600 jobs as it attempts to return to profitability.
Loral Space & Communications–Loral is no longer talking to an investment group about a possible sale, according to Reuters, which said the discussions fell apart over pricing.
—By CNBC's Peter Schacknow
Questions? Comments? Email us at email@example.com